Xiyu Zhu1, Anthony A Grace2. 1. Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania. Electronic address: xiz82@pitt.edu. 2. Department of Neuroscience, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania; Department of Psychology, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: Schizophrenia (SCZ) is a neurodevelopmental disorder with a progressive, prolonged course. Early prevention for SCZ is promising but overall lacks support from preclinical evidence. Previous studies have tested environmental enrichment (EE) in certain models of SCZ and discovered a broadly beneficial effect in preventing behavioral abnormalities relevant, yet not specific, to the disorder. Nonetheless, whether EE can prevent dopamine (DA) dysregulation, a hallmark of psychosis and SCZ, had not been tested. METHODS: Using the MAM (methylazoxymethanol acetate) rat model of schizophrenia and saline-treated control animals, we investigated the long-term electrophysiological effects of prepubertal (postnatal day 21-40) EE on DA neurons, pyramidal neurons in the ventral hippocampus, and projection neurons in the basolateral amygdala. Anxiety-related behaviors in the elevated plus maze and locomotor responses to amphetamine were also analyzed. RESULTS: Prepubertal EE prevented the increased population activity of DA neurons and the associated increase in locomotor response to amphetamine. Prepubertal EE also prevented hyperactivity in the ventral hippocampus but did not prevent hyperactivity in the basolateral amygdala. Anxiety-like behaviors in MAM rats were not ameliorated by prepubertal exposure to EE. CONCLUSIONS: Twenty-day prepubertal EE is sufficient to prevent DA hyperresponsivity in the MAM model, measured by electrophysiological recordings and locomotor response to amphetamine. This effect is potentially mediated by normalizing excessive firing in the ventral hippocampus without affecting anxiety-like behaviors and basolateral amygdala firing. This study identified EE as a useful preventative approach that may protect against the pathophysiological development of SCZ.
BACKGROUND: Schizophrenia (SCZ) is a neurodevelopmental disorder with a progressive, prolonged course. Early prevention for SCZ is promising but overall lacks support from preclinical evidence. Previous studies have tested environmental enrichment (EE) in certain models of SCZ and discovered a broadly beneficial effect in preventing behavioral abnormalities relevant, yet not specific, to the disorder. Nonetheless, whether EE can prevent dopamine (DA) dysregulation, a hallmark of psychosis and SCZ, had not been tested. METHODS: Using the MAM (methylazoxymethanol acetate) rat model of schizophrenia and saline-treated control animals, we investigated the long-term electrophysiological effects of prepubertal (postnatal day 21-40) EE on DA neurons, pyramidal neurons in the ventral hippocampus, and projection neurons in the basolateral amygdala. Anxiety-related behaviors in the elevated plus maze and locomotor responses to amphetamine were also analyzed. RESULTS: Prepubertal EE prevented the increased population activity of DA neurons and the associated increase in locomotor response to amphetamine. Prepubertal EE also prevented hyperactivity in the ventral hippocampus but did not prevent hyperactivity in the basolateral amygdala. Anxiety-like behaviors in MAM rats were not ameliorated by prepubertal exposure to EE. CONCLUSIONS: Twenty-day prepubertal EE is sufficient to prevent DA hyperresponsivity in the MAM model, measured by electrophysiological recordings and locomotor response to amphetamine. This effect is potentially mediated by normalizing excessive firing in the ventral hippocampus without affecting anxiety-like behaviors and basolateral amygdala firing. This study identified EE as a useful preventative approach that may protect against the pathophysiological development of SCZ.
Authors: Mark J Millan; Annie Andrieux; George Bartzokis; Kristin Cadenhead; Paola Dazzan; Paolo Fusar-Poli; Jürgen Gallinat; Jay Giedd; Dennis R Grayson; Markus Heinrichs; René Kahn; Marie-Odile Krebs; Marion Leboyer; David Lewis; Oscar Marin; Philippe Marin; Andreas Meyer-Lindenberg; Patrick McGorry; Philip McGuire; Michael J Owen; Paul Patterson; Akira Sawa; Michael Spedding; Peter Uhlhaas; Flora Vaccarino; Claes Wahlestedt; Daniel Weinberger Journal: Nat Rev Drug Discov Date: 2016-03-04 Impact factor: 84.694
Authors: Christine Konradi; C Kevin Yang; Eric I Zimmerman; Kathryn M Lohmann; Paul Gresch; Harry Pantazopoulos; Sabina Berretta; Stephan Heckers Journal: Schizophr Res Date: 2011-07-13 Impact factor: 4.939
Authors: C E McOmish; E Burrows; M Howard; E Scarr; D Kim; H-S Shin; B Dean; M van den Buuse; A J Hannan Journal: Mol Psychiatry Date: 2007-07-31 Impact factor: 15.992
Authors: Fernanda Crunfli; Caroline Brandão-Teles; Giuliana S Zuccoli; Adriano J M Chaves Filho; Gabriela Maciel Vieira; Danyelle Silva-Amaral; José Alexandre Crippa; João F C Pedrazzi; Danielle S Macêdo; Elaine Del-Bel; Felipe V Gomes Journal: Adv Exp Med Biol Date: 2022 Impact factor: 3.650
Authors: Amanda Kiemes; Felipe V Gomes; Diana Cash; Daniela L Uliana; Camilla Simmons; Nisha Singh; Anthony C Vernon; Federico Turkheimer; Cathy Davies; James M Stone; Anthony A Grace; Gemma Modinos Journal: Neuropsychopharmacology Date: 2021-11-06 Impact factor: 7.853